Biosafety Risk Assessment of a Routine Diagnostic Laboratory During the Coronavirus Disease 2019 Pandemic.

IF 0.7
Orçun Zorbozan, Nergiz Zorbozan, Nevin Turgay
{"title":"Biosafety Risk Assessment of a Routine Diagnostic Laboratory During the Coronavirus Disease 2019 Pandemic.","authors":"Orçun Zorbozan,&nbsp;Nergiz Zorbozan,&nbsp;Nevin Turgay","doi":"10.1089/apb.20.0064","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> In this study, we aimed to perform a biosafety risk assessment to determine measures to be taken against coronavirus disease 2019 (COVID-19) in the routine diagnostic parasitology laboratory of a tertiary health care center. <b>Methods:</b> The risk assessment template included in the supplement of the interim guidance of \"WHO Laboratory Biosafety Guidance Related to COVID-19\" was used for the risk assessment. Risk assessments were carried out for the \"diagnosis of protozoan diseases in respiratory tract samples\" and \"diagnosis of intestinal parasitic diseases\" processes. Initial risk of the laboratory activities was determined before additional risk control measures and overall initial risk was estimated for each process. Overall residual risk of the laboratory activities after risk control measures was estimated for each process. <b>Results:</b> Overall initial risk for both processes was \"very high.\" Fresh microscopic examination steps in both processes and concentration steps for \"diagnosis of intestinal parasite diseases\" were discontinued. All aerosol-generating steps were moved into a class-IIA biological safety cabinet. Overall residual risk was \"medium\" for both processes. <b>Conclusion:</b> This study serves as an example for clinical laboratories regarding how the risk assessment approach in guidelines can be transferred to daily practice.</p>","PeriodicalId":520561,"journal":{"name":"Applied biosafety : journal of the American Biological Safety Association","volume":" ","pages":"S2-S9"},"PeriodicalIF":0.7000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135154/pdf/apb.20.0064.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied biosafety : journal of the American Biological Safety Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/apb.20.0064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In this study, we aimed to perform a biosafety risk assessment to determine measures to be taken against coronavirus disease 2019 (COVID-19) in the routine diagnostic parasitology laboratory of a tertiary health care center. Methods: The risk assessment template included in the supplement of the interim guidance of "WHO Laboratory Biosafety Guidance Related to COVID-19" was used for the risk assessment. Risk assessments were carried out for the "diagnosis of protozoan diseases in respiratory tract samples" and "diagnosis of intestinal parasitic diseases" processes. Initial risk of the laboratory activities was determined before additional risk control measures and overall initial risk was estimated for each process. Overall residual risk of the laboratory activities after risk control measures was estimated for each process. Results: Overall initial risk for both processes was "very high." Fresh microscopic examination steps in both processes and concentration steps for "diagnosis of intestinal parasite diseases" were discontinued. All aerosol-generating steps were moved into a class-IIA biological safety cabinet. Overall residual risk was "medium" for both processes. Conclusion: This study serves as an example for clinical laboratories regarding how the risk assessment approach in guidelines can be transferred to daily practice.

Abstract Image

Abstract Image

2019冠状病毒病大流行期间常规诊断实验室生物安全风险评估
背景:本研究旨在对某三级卫生保健中心常规诊断寄生虫学实验室进行生物安全风险评估,以确定应对冠状病毒病2019 (COVID-19)的措施。方法:采用《世卫组织与COVID-19相关的实验室生物安全指南》临时指南补编中的风险评估模板进行风险评估。对“呼吸道样本中原生动物疾病的诊断”和“肠道寄生虫病的诊断”过程进行了风险评估。在附加风险控制措施之前确定了实验室活动的初始风险,并估计了每个过程的总体初始风险。对每个过程采取风险控制措施后实验室活动的总体剩余风险进行了估计。结果:这两个过程的总体初始风险“非常高”。“诊断肠道寄生虫病”的过程和浓缩步骤中的新鲜显微镜检查步骤已停止。所有产生气溶胶的步骤都被转移到iia类生物安全柜中。两个过程的总体剩余风险为“中等”。结论:本研究为临床实验室如何将指南中的风险评估方法应用于日常实践提供了一个范例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书